Extended Data Fig. 8: A TLR2 agonist is sufficient to inhibit dendritic cell and T cell infiltration into tumors.
From: Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins
a) Experiment schematic for (b-f). C57BL/6 mice were orthotopically injected with 5e5 2838.c3 cells (n = 8 mice per group). Two days later, mice began treatment with 100 µg of Pam3CSK4 q.o.d. Twenty days after tumor implantation, tumors were analyzed b-f) T cells and dendritic cells quantified by flow cytometry. Mann Whitney tests (two sided) were performed. Data are representative of 1 biological replicate. g) Mice of the indicated genotypes were orthotopically implanted with tumor cells as described in Fig. 2h and Extended Data Figure 9e. Left panel: n = 9, 7, 10, and 9 mice were examined for groups 1, 2, 3, and 4 respectively from left to right, over n = 2 biological replicates. Right panel: n = 9 Tlr2+/+ mice and n = 11 Tlr2−/− mice in n = 1 biological replicate. Tumors were analyzed by flow cytometry. Significance was determined by Brown Forsythe and Welch test with Dunnett’s T3 correction (left), and by unpaired t test (right). h) Representative histograms of expression of tumor-reactive T cell markers in Tlr2+/+ or Tlr2−/− mice. For b-g, data are presented as mean values +/− SD.
